Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

About this update from Ginkgo Bioworks Holdings, Inc.

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership, announced in August 2025, to deploy AI-driven, lab-in-the-loop workflows across the biopharma industry. ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans. A Single, Integrated Workflow Across Three Category Leaders ADME-One unites three best-in-class capabilities in one packaged service: Impact on Drug Discovery "With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and ma...

View stock analysis, news, and events for Ginkgo Bioworks Holdings, Inc.